BioInvent International Financial Statement January 1 - December 31, 2020 LUND, Sweden, Feb. 23, 2021 /PRNewswire/ -- "BioInvent has started 2021 with significant positive momentum We reported promising interim efficacy data from the ongoing Phase I/IIa trial of our lead drug candidate BI-1206.The company also closed a successful SEK 962 million financing round, expanding our institutional shareholder base. Furthermore, we announced the expansion of our clinical pipeline to include two further drug candidates for the treatment of solid tumors." - Martin Welschof, CEO BioInvent Financial information - Profit/loss after tax SEK 28.5 (-40.9) million. - Profit/loss after tax per share before and after dilution SEK 0.74 (-2.04).